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Abstract
Introduction: Prospective epidemiologic studies have consistently shown that levels of circulating androgens in
postmenopausal women are positively associated with breast cancer risk. However, data in premenopausal women
are limited.
Methods: A case-control study nested within the New York University Women’s Health Study was conducted. A
total of 356 cases (276 invasive and 80 in situ) and 683 individually-matched controls were included. Matching
variables included age and date, phase, and day of menstrual cycle at blood donation. Testosterone,
androstenedione, dehydroandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured
using direct immunoassays. Free testosterone was calculated.
Results: Premenopausal serum testosterone and free testosterone concentrations were positively associated with
breast cancer risk. In models adjusted for known risk factors of breast cancer, the odds ratios for increasing
quintiles of testosterone were 1.0 (reference), 1.5 (95% confidence interval (CI), 0.9 to 2.3), 1.2 (95% CI, 0.7 to 1.9),
1.4 (95% CI, 0.9 to 2.3) and 1.8 (95% CI, 1.1 to 2.9; Ptrend = 0.04), and for free testosterone were 1.0 (reference), 1.2
(95% CI, 0.7 to 1.8), 1.5 (95% CI, 0.9 to 2.3), 1.5 (95% CI, 0.9 to 2.3), and 1.8 (95% CI, 1.1 to 2.8, Ptrend = 0.01). A
marginally significant positive association was observed with androstenedione (P = 0.07), but no association with
DHEAS or SHBG. Results were consistent in analyses stratified by tumor type (invasive, in situ), estrogen receptor
status, age at blood donation, and menopausal status at diagnosis. Intra-class correlation coefficients for samples
collected from 0.8 to 5.3 years apart (median 2 years) in 138 cases and 268 controls were greater than 0.7 for all
biomarkers except for androstenedione (0.57 in controls).
Conclusions: Premenopausal concentrations of testosterone and free testosterone are associated with breast
cancer risk. Testosterone and free testosterone measurements are also highly reliable (that is, a single measurement
is reflective of a woman’s average level over time). Results from other prospective studies are consistent with our
results. The impact of including testosterone or free testosterone in breast cancer risk prediction models for
women between the ages of 40 and 50 years should be assessed. Improving risk prediction models for this age
group could help decision making regarding both screening and chemoprevention of breast cancer.
Introduction
Prospective epidemiologic studies have consistently
shown that circulating androgens in postmenopausal
women are positively associated with breast cancer risk
[1-8], an association which is thought to be largely due
to their role as precursors of estrogens. Positive associa-
tions have also been reported for androgens in
premenopausal women but data are limited to date,
with the majority of studies having small numbers of
cases [9-17]. If results in premenopausal women are
confirmed, androgens could be considered for inclusion
in breast cancer risk prediction models, such as the Gail
model [18]. Improving breast cancer risk prediction
models could be particularly valuable for women
between the ages of 40 and 50, as they could help with
decisions on screening, since guidelines for this age
group are not consistent [19,20]. In addition, improved
models might help younger women with an elevated
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risk of breast cancer decide whether to take tamoxifen
for chemoprevention, as is recommended [21,22].
Tamoxifen has been approved by the US Food and
Drug Administration for chemoprevention in women
age 35 or older with a 5-year Gail-model risk greater
than 1.66%, but is not often used in practice for this
purpose [23,24]. A better understanding of the associa-
tion between premenopausal concentrations of andro-
gens and breast cancer risk is also important because
some experimental studies [25,26], although not all [27],
have suggested that androgens may protect against
breast cell proliferation in an estrogen-rich environment,
such as the time period before menopause. Finally, it is
also important to assess the association between andro-
gens and breast cancer risk because androgens have
been advocated for relief of sexual symptoms such as
low libido [28], including in older premenopausal
women [29].
We report here the results of a case-control study
nested within the New York University (NYU) Women’s
Health Study cohort. Prediagnostic concentrations of
testosterone, androstenedione, dehydroepiandrosterone
sulfate (DHEAS) and sex hormone-binding globulin
(SHBG) were measured in serum samples from 356 inci-
dent cases and 683 controls who were premenopausal at
enrollment (time of initial blood donation), and the
association of these biomarkers with subsequent risk of
breast cancer was assessed.
Materials and methods
Study Population
The NYU Women’s Health Study (NYUWHS) enrolled
14,274 women 34 to 65 years old at a breast cancer
screening center in New York City between 1985 and
1991 [30]. Women who had been pregnant or taken hor-
monal medications in the six months preceding their
visit were excluded. After written informed consent was
obtained, demographic, medical, anthropometric, repro-
ductive, and dietary data were collected through self-
administered questionnaires. Non-fasting peripheral
venous blood was drawn prior to breast examination and
serum samples were stored at -80°C for subsequent bio-
chemical analyses. Up until 1991, women who returned
to the clinic for annual breast cancer screening were
asked to donate blood at each of their visits. For 52% of
the women, two or more blood samples were collected.
Women were classified as premenopausal at enroll-
ment/first blood donation if they reported at least one
menstrual cycle in the six months prior to their visit. To
determine the phase of cycle at blood donation, the
start date of the menstrual period prior to the visit was
recorded, and women were asked to return a postcard
indicating the start date of their next menstrual cycle.
Seventy-two percent of the women returned the
postcard. For women with length of cycle 20 to 41 days,
phase of cycle was calculated based on the number of
days between the date of blood donation and the start
date of the next menses: < 12 days: luteal; 12 to 16 days:
peri-ovulatory; 17 to 19 days: late follicular; ≥20 days:
early follicular. For the 15% of women who did not
return the postcard but reported regular menstrual
cycles, the date of menstrual period prior to the visit
and the usual length of cycle were used to compute the
phase of cycle at blood donation. Women who had had
a hysterectomy without total oophorectomy prior to
natural menopause and were less than 52 years of age at
enrollment were also classified as premenopausal, with
subsequent verification of menopausal status by follicle-
stimulating hormone (FSH) measurements on a nested
case-control basis. Women with a concentration < 12.75
mIU/mL were confirmed as premenopausal. For these
women (7%), the phase of cycle at blood donation was
coded as unknown. Phase of cycle was also coded as
unknown for women who did not return the postcard
and reported having irregular cycles and for women
who returned the postcard but had a length of cycle less
than 20 or more than 41 days (13%). The study was
approved by the Institutional Review Board at the New
York University School of Medicine.
Nested case-control study of breast cancer
Breast cancer cases were identified through active fol-
low-up of the cohort by mailed questionnaires approxi-
mately every two to four years and telephone interviews
for non-respondents, as well as record linkages with
state cancer registries in New York, New Jersey, and
Florida, and with the US National Death Index. A cap-
ture-recapture analysis estimated the breast cancer case
ascertainment rate in our cohort to be 95% [31]. Only
incident cases (that is, diagnosed at least six months
after blood donation) were included. Medical and
pathology reports were reviewed to confirm the
diagnosis.
For each case, two controls were selected at random
from the appropriate risk set. The risk set for a case
consisted of all women premenopausal at enrollment
who were alive and free of cancer at the time of diagno-
sis of the case (index date) and who matched the case
on age at enrollment/first blood donation (± 6 months),
date of enrollment (± 3 months), number (0, 1, 2+) and
dates (± 6 months) of subsequent blood donations, and
phase (early follicular, late follicular, peri-ovulatory,
luteal, unknown) and day of menstrual cycle at the first
blood donation.
Laboratory analyses
All assays were conducted in the Hormones and Cancer
Group at the International Agency for Research on
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Cancer in Lyon, France. Assays were selected based on
the results of a validity study [32]. Testosterone and
DHEAS were measured by direct radioimmunoassays
from Immunotech (Marseille, France), androstenedione
and FSH by direct double-antibody radioimmunoassays
from DSL (Diagnostic System Laboratories, Webster,
Texas), and SHBG by a direct ‘sandwich’ immunoradio-
metric assay (Cis-Bio, Gif-sur-Yvette, France). Mean
intra-batch and inter-batch coefficients of variation were
8.7% and 15.8% for testosterone, 7.8% and 13.5% for
androstenedione, 5.4% and 14.7% for DHEAS and 5.6%
and 13.5% for SHBG. Free testosterone was calculated
using mass action equations and the concentrations of
testosterone and SHBG [33].
Statistical methods
Case and control characteristics were compared using
the conditional logistic regression model, to take into
account the individual matching. Median, 10th and 90th
percentiles were calculated for the hormonal measure-
ments and a mixed-effects regression model accounting
for the matching was used to compare concentrations in
cases and controls. Odds ratios were estimated using
conditional logistic regression. Biomarkers were ana-
lyzed as quintiles based on the distribution of cases and
controls combined, and trend tests were carried out
using ordered categorical variables. We also conducted
an analysis using the mean hormone level for women
who had two samples, and the single available measure-
ment for the remaining women. Finally, each biomarker
was also analyzed after log2-transformation to estimate
odds ratios corresponding to a doubling in concentra-
tion and to compute a trend test on the continuous
scale. Adjusted models included known risk factors for
breast cancer, that is, age at menarche, family history of
breast cancer, parity, age at first birth, history of breast
biopsy, and body mass index. Analyses were also done
stratifying by tumor type (invasive and in situ), estrogen
receptor status, age at enrollment, menopausal status at
index date, lag time between blood donation and diag-
nosis of the case, and in the subgroup of women who
had reported a history of regular menstrual cycles as
well as five to seven cycles in the six months prior to
blood donation. Analyses stratified by body mass index
(BMI) and menopausal status at diagnosis and in the
subgroup of women with five to seven regular menstrual
cycles in the six months prior to blood donation were
carried out using unconditional logistic regression, con-
trolling for the matching factors, to avoid exclusion
from the analysis of matched sets whose case and con-
trols would be in different strata. All stratified analyses
were carried out on log2-transformed hormones because
of the smaller sample sizes in subgroups. The P-value
obtained when adding a cross-product term to the
model containing main effects was used to assess inter-
action. All statistical tests were two-sided.
The intra-class correlation coefficient (ICC) [34] was
used to assess the temporal reliability of the biomarker
measurements using two samples collected at different
time points in cases and controls who donated blood
more than once.
Results
Among the 7,220 (50.6%) women who were premeno-
pausal at the time of initial blood donation, 366 breast
cancer cases (285 invasive and 81 in situ) were diag-
nosed by 1 January 2000. Ten cases were excluded
because of FSH concentrations compatible with postme-
nopausal status. As a result, 356 cases (276 invasive and
80 in situ) are included in this analysis. Among the initi-
ally selected individually-matched controls, 29 were
excluded because of their FSH concentrations, resulting
in the inclusion of 683 controls in this analysis. For 138
cases and 268 controls, serum samples collected at two
separate visits were analyzed.
Table 1 presents descriptive statistics of the study
participants. Fifty-five percent of the cases were
between the ages of 34 and 44 at blood donation.
Fourteen percent of the cases were diagnosed before
age 45 and 70% before age 55. As expected, there was
a higher proportion of nulliparous women among
cases than controls (40% versus 34%, P = 0.04) and
cases tended to have a later age at first full-term preg-
nancy than controls (P = 0.03). There was also a
higher proportion of women with a family history of
breast cancer among cases than controls (P = 0.004).
There was no difference between cases and controls in
the proportions of overweight (25 to 29.9 kg/m2; 21%
and 22%, respectively) and obese (≥30 kg/m2; 10% in
both groups) women. Seventy-six percent of the cases
and 78% of the controls had a history of regular cycles
and also reported five to seven cycles in the six
months prior to enrollment.
As was observed in longitudinal studies of premeno-
pausal women [35], the highest concentrations of andro-
gens were observed in the peri-ovulatory phase and the
highest concentrations of SHBG in the luteal phase
(data not shown). However, none of these differences
were statistically significant. Table 2 shows hormone
concentrations in cases and controls. Testosterone con-
centrations were higher in cases than controls (median:
0.90 nmol/L versus 0.83 nmol/L, P = 0.01) as were free
testosterone concentrations (11.91 pmol/L versus 11.02
pmol/L, P = 0.01). The median androstenedione concen-
tration was marginally higher in cases than controls
(3.90 nmol/L versus 3.74 nmol/L, P = 0.08), whereas no
statistically significant difference was observed for
DHEAS and SHBG.
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Table 1 Case and control subject characteristics
Characteristic Case subjects
(n = 356)
Control subjects
(n = 683)
P-valuea
Age at enrollment, years matched
34 to 40 77 (22%) 152 (22%)
40 to 44 118 (33%) 235 (35%)
45 to 49 110 (31%) 205 (30%)
≥50 51 (14%) 91 (13%)
Age at diagnosis, years
< 45 48 (14%)
45 to 49 99 (28%)
50 to 54 101 (28%)
≥55 108 (30%)
Menopausal status at index date 0.06b
Premenopausal 152 (49%) 316 (52%)
Postmenopausal 161 (51%) 293(48%)
Missing 43 74
Age at menarche, years 0.49c
< 12 87 (25%) 157 (23%)
12 97 (27%) 167 (25%)
13 108 (30%) 210 (31%)
> 13 64 (18%) 144 (21%)
Missing 0 5
Nulliparous (%) 142 (40%) 230 (34%) 0.04b
Age at first full-term pregnancy, years 0.03c
< 25 91 (44%) 238 (54%)
25 to 30 54 (26%) 122 (27%)
30 to 34 41 (20%) 60 (14%)
≥35 21 (10%) 24 (5%)
Missing 7 9
First-degree family history of breast cancer (%) 0.004b
No 264 (74%) 550 (81%)
Yes, one relative ≥45 years-old 64 (18%) 106 (15%)
Yes, one relative < 45 years-old or
more than one relative
28 (8%) 27 (4%)
History of breast biopsy (%) 79 (22%) 127 (19%) 0.11b
Ever use of oral contraceptives (%) 175 (56%) 362 (59%) 0.37b
Missing 42 67
Body mass index (kg/m2) 0.19c
< 20 55 (16%) 70 (10%)
20 to 22.4 111 (31%) 233 (34%)
22.5 to 24.9 79 (22%) 164 (24%)
25 to 29.9 76 (21%) 149 (22%)
≥30 34 (10%) 66 (10%)
Missing 1 1
Menstrual cycle regularity and number of periods in six months prior to blood donation 0.64b
Irregular cycles 78 (23%) 139 (21%)
Regular cycles
< 5 cycles in 6 months 3 (1%) 8 (1%)
5 to7 cycles in 6 months 259 (76%) 516 (78%)
> 7 cycles in 6 months 2 2
Missing 14 18
aBased on conditional logistic regression.bP-value for unordered categorical variable, except for family history of breast cancer (ordered categorical variable). cP-
value for variable on the continuous scale.
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Table 3 reports odds ratios for breast cancer by quin-
tiles of hormone concentrations. In multivariate-
adjusted models, risk of breast cancer increased signifi-
cantly with concentrations of testosterone (P = 0.04)
and free testosterone (P = 0.01), with odds ratio (95%
CI) of 1.8 (1.1, 2.9) and 1.8 (1.1, 2.8), respectively, for
women in the highest versus lowest quintile. The
increase in risk appeared more linear for free testoster-
one (odds ratios for quintiles were 1.0, 1.2, 1.5, 1.5 and
1.8) than testosterone (odds ratios for quintiles were 1.0,
1.5, 1.2, 1.4 and 1.8). A marginally significant trend (P =
0.07) of increasing risk with increasing concentration of
androstenedione was also observed, while no significant
association was observed between concentrations of
Table 2 Median (10th and 90th percentiles) of hormone
concentrations in cases and controls
Case subjects
(n = 356)
Control
subjects
(n = 683)
P-
value
Testosterone, nmol/L 0.90 (0.41, 2.07) 0.83 (0.31, 1.87) 0.01
Free testosterone, pmol/
L
11.91 (4.92,
32.01)
11.02 (3.70,
27.81)
0.01
Androstenedione, nmol/
L
3.90 (1.97, 6.80) 3.74 (1.80, 6.53) 0.08
DHEAS, μmol/L 3.58 (1.57, 7.22) 3.33 (1.54, 6.75) 0.50
SHBG, nmol/L 48.3 (22.3, 87.2) 49.4 (21.7, 89.5) 0.64
DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.
Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer by hormone concentration
Quintiles P for trend
1 2 3 4 5
Testosterone
Cutpoints, nmol/L < 0.50 0.50 to 0.74 0.75 to 0.99 1.00 to 1.41 > 1.41
#cases/#controlsa 58/139 75/124 63/134 70/129 80/118
Unadjusted ORb, c (95% CI) 1.0 1.5 (1.0, 2.3) 1.2 (0.8, 1.9) 1.4 (0.9, 2.2) 1.7 (1.1, 2.7) 0.06
Adjusted ORb, c (95% CI) 1.0 1.5 (0.9, 2.3) 1.2 (0.7, 1.9) 1.4 (0.9, 2.3) 1.8 (1.1, 2.9) 0.04
Adjusted ORb, c, d (95% CI) 1.0 1.6 (1.0, 2.6) 1.4 (0.9, 2.2) 1.6 (1.0, 2.6) 2.2 (1.3, 3.5) 0.03
Free Testosterone
Cutpoints, pmol/L < 6.02 6.02 to 9.11 9.12 to 13.91 13.92 to 20.92 > 20.92
#cases/#controlsa 60/136 63/134 72/125 69/128 81/116
Unadjusted ORb (95% CI) 1.0 1.1 (0.7, 1.7) 1.3 (0.9, 2.1) 1.3 (0.8, 2.0) 1.6 (1.0, 2.5) 0.03
Adjusted OR b, c (95% CI) 1.0 1.2 (0.7, 1.8) 1.5 (0.9, 2.3) 1.5 (0.9, 2.3) 1.8 (1.1, 2.8) 0.01
Adjusted ORb, c, d (95% CI) 1.0 1.3 (0.8, 2.0) 1.5 (1.0, 2.4) 1.4 (0.9, 2.3) 1.9 (1.2, 2.9) 0.01
Androstenedione
Cutpoints, nmol/L < 2.45 2.45 to 3.37 3.38 to 4.32 4.33 to 5.58 > 5.58
#cases/#controlsa 65/138 72/120 63/139 70/132 80/123
Unadjusted ORb (95% CI) 1.0 1.2 (0.8, 1.9) 1.1 (0.7, 1.7) 1.2 (0.8, 1.9) 1.5 (1.0, 2.5) 0.11
Adjusted OR b, c (95% CI) 1.0 1.3 (0.8, 2.0) 1.1 (0.7, 1.7) 1.3 (0.8, 2.1) 1.7 (1.1, 2.7) 0.07
Adjusted ORb, c, d (95% CI) 1.0 1.5 (0.9, 2.4) 1.0 (0.6, 1.6) 1.3 (0.8, 2.2) 1.6 (1.0, 2.7) 0.11
DHEAS
Cutpoints, μmol/L < 2.04 2.04 to 2.88 2.89 to 3.94 3.95 to 5.24 > 5.24
#cases/#controlsa 64/139 70/134 69/134 80/124 71/132
Unadjusted ORb (95% CI) 1.0 1.2 (0.8, 1.8) 1.2 (0.7, 1.8) 1.5 (0.9, 2.2) 1.2 (0.8, 1.9) 0.25
Adjusted OR b, c (95% CI) 1.0 1.1 (0.7, 1.7) 1.1 (0.7, 1.8) 1.5 (0.9, 2.3) 1.3 (0.8, 2.0) 0.14
Adjusted ORb, c, d (95% CI) 1.0 1.1 (0.7, 1.8) 1.1 (0.7, 1.8) 1.3 (0.8, 2.0) 1.3 (0.8, 2.1) 0.20
SHBG
Cutpoints, nmol/L < 30.5 30.5 to 43.6 43.6 to 54.8 54.8 to 72.9 > 72.9
#cases/#controlsa 71/133 76/129 68/137 74/131 65/140
Unadjusted ORb (95% CI) 1.0 1.1 (0.8, 1.7) 0.9 (0.6, 1.4) 1.1 (0.7, 1.7) 0.9 (0.6, 1.3) 0.50
Adjusted OR b, c (95% CI) 1.0 1.1 (0.7, 1.7) 0.9 (0.6, 1.4) 1.1 (0.7, 1.5) 0.9 (0.6, 1.3) 0.37
Adjusted ORb, c, d(95% CI) 1.0 1.0 (0.6, 1.5) 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 0.7 (0.4, 1.2) 0.19
aThe number of subjects varies for each hormone depending on the number of the values below the detection limit. bControlling for age, date, and phase and
day of cycle at blood donation through matching and use of conditional logistic regression. cAdjusted for age at menarche (< 12, 12, 13, > 13, missing), family
history of breast cancer (no, one affected first-degree relative > 45 yrs old, one affected first degree relative < 45 yrs old or more than one affected first-degree
relative), parity/age at first birth (≤20 years at first full-term pregnancy, 21-25 years at first full-term pregnancy, 26-30 years at first full-term pregnancy, > 30 years
at first full-term pregnancy, nulliparous, missing), history of breast biopsy, and body mass index (< 20, 20-22.5, 22.6-24.9, 25-29.9, 30+, missing). dUsing the
average of two measurements for women for whom two blood samples were available and one measurement for all other women and adjusting for all factors
listed in c. DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.
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DHEAS and SHBG with breast cancer risk. Associations
were similar in analyses using the mean hormone level
for women who had two samples and the single avail-
able measurement for the remaining women, except for
testosterone for which higher odds ratios were observed
when the average was used if available.
Table 4 reports odds ratios associated with a doubling
of biomarker concentrations for all women, as well as
by various subject characteristics. Although the odds
ratios varied in magnitude according to subgroups and
were not always consistently statistically significant, the
associations between testosterone and free testosterone
and breast cancer risk were usually in the same direc-
tion, and none of the tests for interaction was signifi-
cant. In particular, odds ratios associated with a
doubling in testosterone or free testosterone were ele-
vated for invasive and in situ tumors, as well as for
tumors diagnosed before and after menopause. Odds
ratios greater than one were also observed for estrogen
receptor-negative tumors, although the associations
were weaker than for estrogen receptor-positive tumors
and not statistically significant.
Table 5 shows the ICCs for androgens and SHBG
measured at two visits a median of two years (range 0.8
to 5.3 years) apart. ICCs were very similar in cases and
controls. The lowest ICC was observed for androstene-
dione (0.57, 95% CI: 0.49, 0.65) with all other ICCs
greater than 0.7.
Discussion
We observed positive associations between premenopau-
sal concentrations of total and free testosterone and
breast cancer risk, with women in the highest quintile
having a risk approximately 80% greater than women in
the lowest quintile. We also observed a marginally sig-
nificant positive association with androstenedione but
no association with DHEAS or SHBG. The observation
of similar associations (except for testosterone for which
the odds ratios increased slightly) in an analysis using
the mean hormone level for women who had two sam-
ples and the single available measurement for the
remaining women strengthened our conclusions. There
was no evidence of heterogeneity in the associations of
total and free testosterone with breast cancer risk in
subgroups according to tumor type, estrogen receptor
status, age and BMI at enrollment, menopausal status at
diagnosis and lag time between blood donation and
diagnosis.
Two prospective studies also reported statistically sig-
nificant positive associations between premenopausal
concentrations of testosterone and free testosterone and
breast cancer risk [14,17], three reported non-significant
positive associations [10,12,16], and the smallest (17
cases) reported no association [9]. Overall, results are
consistent across studies, despite variations in the phase
of menstrual cycle when blood was drawn, follow-up
duration, menopausal status at diagnosis and assay used
(table 6). In particular, the two largest studies (the Eur-
opean Prospective Investigation into Cancer and Nutri-
tion (EPIC) study and this one) both reported
statistically significant positive trends for testosterone
level and breast cancer risk; free testosterone was not
evaluated in the EPIC study. We also observed a high
temporal reliability of total testosterone and free testos-
terone over a median time of two years, as was also
reported by others [36,37].
It has been suggested that including circulating con-
centrations of sex hormones could improve risk predic-
tion models [38,39]. In fact, imputed postmenopausal
concentrations of estradiol improved the discriminatory
accuracy of the log-incidence model for breast cancer
risk prediction developed by Rosner and Colditz [40],
although only modestly. Estrogens, though, are not good
candidates for inclusion in risk prediction models of
breast cancer in premenopausal women because no con-
sistent association has been demonstrated with breast
cancer risk in these women [9-11,14,16,17,41], which
may be due to the large variations in estrogen concen-
trations over the menstrual cycle. The positive associa-
tion of premenopausal testosterone and free
testosterone concentrations with breast cancer risk,
combined with the high temporal reliability of these bio-
markers, suggests that it would be of interest to examine
whether inclusion of one or the other could improve
breast cancer risk prediction models. Testosterone was
found to be associated with risk of breast cancer across
strata of predicted risk (using either the Gail or the Ros-
ner and Colditz models), suggesting that it may convey
information about risk independent of the factors
included in these models [42]. Free testosterone seems
of particular interest for risk prediction models, because
it is thought to be the fraction most readily available
biologically, and because the association with risk
appears more linear. Improving risk prediction models
for younger women could have implications for both
screening and chemoprevention decision making. For
women between the ages of 40 and 49 years, recom-
mendations for breast cancer screening are not consis-
tent. Whereas the American Cancer Society and some
professional societies continue to recommend annual
mammography starting at age 40 [43], the US Preventive
Services Task Force recommended in 2009 to start
screening at age 50, rather than at age 40, in the
absence of known underlying genetic mutation or his-
tory of chest radiation [19]. Regarding breast cancer pre-
vention, there is a net benefit of tamoxifen for women
below age 50 who have a Gail model five-year risk
greater than 1.66% [44] and tamoxifen has been
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Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for a doubling in hormone concentration for all women
and according to subject characteristicsa
Characteristic Hormone
(number of cases) Testosterone Free
Testosterone
Androstenedione DHEAS SHBG
All women (n = 354)
OR (95% CI) 1.6 (1.2, 2.3) 1.3 (1.1, 1.5) 1.3 (1.0, 1.7) 1.1 (0.9, 1.4) 0.9 (0.8, 1.1)
P-value 0.01 0.003 0.07 0.31 0.47
Tumor type
Invasive (n = 274)
OR (95% CI) 1.5 (1.1, 2.2) 1.2 (1.0, 1.4) 1.3 (0.9, 1.8) 1.1 (0.8, 1.4) 1.0 (0.8, 1.2)
P-value 0.03 0.02 0.11 0.60 0.84
In situ (n = 80)
OR (95% CI) 2.3 (0.9, 5.9) 1.4 (1.0, 2.1) 2.0 (0.9, 4.5) 1.6 (0.9, 2.8) 0.8 (0.5, 1.3)
P-value 0.09 0.07 0.10 0.14 0.37
Estrogen receptor statusb
Positive (n = 104)
OR (95% CI) 2.4 (1.2, 4.6) 1.6 (1.2, 2.2) 2.2 (1.3, 3.8) 1.2 (0.8, 1.8) 0.9 (0.6, 1.3)
P-value 0.01 0.003 0.01 0.42 0.56
Negative (n = 60)
OR (95% CI) 1.7 (0.7, 4.3) 1.2 (0.9, 1.8) 0.7 (0.3, 1.6) 1.4 (0.7, 2.6) 0.8 (0.5, 1.4)
P-value 0.25 0.26 0.37 0.34 0.41
Age at enrollmentc
< 40 yrs (n = 77)
OR (95% CI) 1.7 (0.7, 4.2) 1.3 (0.9, 2.0) 1.3 (0.6, 2.7) 0.9 (0.5, 1.5) 0.7 (0.4, 1.2)
P-value 0.27 0.19 0.45 0.61 0.17
40- to yrs (n = 117)
OR (95% CI) 1.4 (0.7, 2.6) 1.1 (0.8, 1.4) 1.1 (0.7, 1.8) 1.1 (0.8, 1.6) 1.2 (0.8, 1.8)
P-value 0.33 0.50 0.72 0.53 0.36
≥45 yrs (n = 160)
OR (95% CI) 1.9 (1.2, 3.2) 1.4 (1.1, 1.7) 1.5 (1.0, 2.3) 1.2 (0.9, 1.7) 0.9 (0.7, 1.2)
P-value 0.01 0.004 0.08 0.21 0.57
Menopausal status at diagnosisd, e
Pre (n = 152)
OR (95% CI) 1.4 (0.8, 2.3) 1.1 (0.9, 1.4) 1.0 (0.7, 1.5) 1.1 (0.8, 2.5) 1.0 (0.8, 1.4)
P-value 0.23 0.36 0.98 0.56 0.80
Post (n = 161)
OR (95% CI) 1.7 (1.1, 2.6) 1.3 (1.1, 1.6) 1.3 (0.9, 1.9) 1.2 (0.8, 1.6) 0.9 (0.7, 1.1)
P-value 0.02 0.006 0.18 0.39 0.26
BMId
< 25 kg/m2 (n = 239)
OR (95% CI) 1.8 (1.2, 2.6) 1.3 (1.1, 1.5) 1.2 (0.9, 1.6) 1.3 (1.0, 1.6) 0.9 (0.7, 1.1)
P-value 0.003 0.003 0.30 0.08 0.41
25 to 29.9 kg/m2 (n = 74)
OR (95% CI) 2.4 (1.1, 5.0) 1.5 (1.1, 2.1) 1.9 (1.0, 3.5) 1.3 (0.8, 2.1) 1.1 (0.8, 1.7)
P-value 0.02 0.01 0.05 0.29 0.58
≥30 kg/m2 (n = 108)
OR (95% CI) 1.5 (0.8, 2.7) 1.2 (0.9, 1.6) 1.6 (1.0, 2.5) 1.0 (0.7, 1.5) 1.1 (0.8, 1.5)
P-value 0.20 0.11 0.08 0.95 0.64
Lag time between blood donation and diagnosisf
< 7 yrs (n = 154)
OR (95% CI) 2.0 (1.1, 3.5) 1.3 (1.0, 1.7) 1.3 (0.9, 2.1) 1.4 (1.0, 1.9) 1.0 (0.8, 1.5)
P-value 0.02 0.04 0.20 0.06 0.78
≥7 yrs (n = 200)
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approved for chemoprevention in such women. Use of
tamoxifen for prevention of breast cancer, though, has
been limited [23,24]. It has been shown that the higher
the risk of breast cancer relative to the risk of adverse
events, the more likely a woman is to accept tamoxifen
chemoprevention [45]. Factors helping to predict more
accurately the absolute risk of breast cancer might thus
lead to increased acceptance of chemoprevention by the
women most likely to benefit and, therefore, result in a
larger number of prevented breast cancers. A challenge
that needs to be addressed prior to incorporation of cir-
culating hormone levels in risk prediction models,
though, is standardization of assay methods [38,46,47].
Positive associations between circulating androgens in
postmenopausal women and risk of breast cancer have
been observed consistently [1], although the association
may vary according to the estrogen receptor (ER) status
of the tumor. Whereas most studies found a positive
association with ER-positive tumors [4,8,48,49], no sig-
nificant association was observed in three studies
[4,6,48], and the largest study to date found a significant
inverse, rather than positive, association with ER-nega-
tive tumors [49]. Notwithstanding these differences, the
main mechanism proposed to explain the increase in
risk observed among postmenopausal women is the aro-
matization of androgens into estrogens in peripheral
adipose tissue [50]. Because of the reduced production
of estrogens by the ovaries, peripheral production is an
important contributor to circulating concentrations of
estrogens after menopause. This mechanism is thought
to contribute to the well documented positive associa-
tion between BMI and breast cancer risk observed after
menopause [51]. It is unlikely, though, that this mechan-
ism explains the association observed between andro-
gens and breast cancer in premenopausal women
because estrogens are mostly produced by the ovaries
prior to menopause. Further, under this mechanism,
one would expect a positive association between BMI
and breast cancer risk in premenopausal women, as is
seen in post-menopausal women, since more aromatiza-
tion of androgens in adipose tissue is expected with
increased BMI. However, although we did not observe
an association of BMI with breast cancer risk in our
study, an inverse, rather than positive, association
between BMI and breast cancer risk in premenopausal
women has been found in most studies [52,53]. Addi-
tional evidence against an important role of this
mechanism is the observation made by Eliassen et al.
that adjustment for concentrations of estradiol in pre-
menopausal women did not affect risk estimates asso-
ciated with testosterone concentrations [16]. It is of
interest that we observed an association in women with
regular cycles, as well as women of normal weight, sug-
gesting that androgen concentrations increase breast
cancer risk even in women with no evidence of
hyperandrogenism.
In addition to their role as estrogen precursors, it has
been proposed that androgens directly impact cell pro-
liferation [54,55], possibly through binding to androgen
receptors which are present in both normal breast tissue
and most breast cancers [56]. Results from experimental
studies, though, have been inconsistent, with some stu-
dies [25,26] reporting an inhibitory effect of androgens
on estrogen-induced breast cell proliferation, while
others did not [27]. The only human study that exam-
ined the effect of testosterone on breast cell prolifera-
tion found that postmenopausal women who received
testosterone (300 μg/day patch) in addition to hormone
replacement therapy (2 mg estradiol and 1 mg
Table 5 ICCs (95% CI) for hormonal biomarkers
Cases
N = 138
Controls
N = 268
Testosterone 0.74 (0.65 - 0.81) 0.78 (0.73 - 0.82)
Androstenedione 0.58 (0.46 - 0.68) 0.57 (0.49 - 0.65)
DHEAS 0.82 (0.76 - 0.87) 0.76 (0.70 - 0.81)
SHBG 0.86 (0.81 - 0.90) 0.78 (0.73 - 0.82)
Free testosterone 0.86 (0.81 - 0.90) 0.82 (0.78 - 0.86)
DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.
Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for a doubling in hormone concentration for all women
and according to subject characteristicsa (Continued)
OR (95% CI) 1.5 (1.0, 2.3) 1.3 (1.0, 1.5) 1.3 (0.9, 1.9) 1.0 (0.7, 1.3) 0.8 (0.6, 1.1)
P-value 0.07 0.02 0.17 0.80 0.22
5 to7 cycles in 6 months prior to enrollment and regular
cyclesd (n = 253)
OR (95% CI) 1.6 (1.1, 2.3) 1.2 (1.1, 1.5) 1.3 (1.0, 1.8) 1.1 (0.9, 1.5) 0.9 (0.8, 1.2)
P-value 0.02 0.01 0.07 0.29 0.59
aAdjusted for age at menarche (< 12, 12, 13, > 13, missing), family history of breast cancer (no, one affected first-degree relative > 45 yrs old, one affected first
degree relative < 45 yrs old or more than one affected first-degree relative), parity/age at first birth (≤20 years at first full-term pregnancy, 21 to 25 years at first
full-term pregnancy, 26 to 30 years at first full-term pregnancy, > 30 years at first full-term pregnancy, nulliparous, missing), history of breast biopsy, and body
mass index (< 20, 20-22.5, 22.6-24.9, 25-29.9, 30+, missing). b0.05 <Pinteraction < 0.15 for androstenedione.
c0.05 <Pinteraction < 0.15 for free testosterone.
dUsing
unconditional logistic regression, adjusting for matching factors in addition to factors listed in a. e 0.05 <Pinteraction < 0.15 for free testosterone.
f0.05 <Pinteraction <
0.15 for SHBG. DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.
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norethisterone acetate) did not have an increase in cell
proliferation, while a more than five-fold increase in cell
proliferation was observed in women who received only
the estrogen + progestin therapy [57]. These studies,
though, were conducted in primates or in women in the
postmenopausal stage who received estrogens orally, the
effect of which may differ from that of endogenous hor-
mones. For instance, oral estrogens are known to
increase production of SHBG and reduce the concentra-
tions of free testosterone [58]. It is, therefore, not clear
whether results of these studies apply to endogenous
androgens in premenopausal women. Additional
research is needed to explain why circulating concentra-
tions of androgens in premenopausal women are asso-
ciated with an increase in risk of breast cancer.
Androgens, in particular testosterone, have been pro-
posed for relief of menopausal symptoms, in particular
sexual desire deficit [28]. As symptoms may start well
before menopause, androgen therapies may be pre-
scribed beginning in the late premenopausal years
[29,59]. In light of the increased risk of breast cancer
associated with higher concentrations of circulating
androgens both pre- and post-menopause, and the
results of two prospective studies that reported an
increased risk of breast cancer in women receiving
estrogen + testosterone therapy [60,61], although this
association was significant only in one of the two studies
[60], caution should be exercised regarding long-term
prescription of androgens.
The NYUWHS was designed primarily to examine the
association of endogenous sex hormones with risk of
breast cancer. We therefore excluded women taking
exogenous estrogens and collected data on date of next
menstrual period which allowed us to calculate the
phase of cycle more precisely than some other studies.
Other strengths of our study include the large number
of cases, which allowed us to examine various subgroups
and the availability of two serum samples in a fairly
large number of both cases and controls which allowed
us to show that a single androgen concentration
Table 6 Prospective studies of testosterone and breast cancer risk in premenopausal womena
Study Number
of
Cases/
Controls
Mean (SD)
age at
baseline for
cases, yrs
Phase of
cycle
when
blood
was
drawn
Mean
follow-up
duration,
yrs
Menopausal
status
at diagnosis
Assay method Testosterone
Odds Ratiob
(95% CI)
Ptrend Free
Testosteronec
Odds Ratiob
(95% CI)
Ptrend
Guernsey
(Thomas
et al.
1997)
62/182 40.9 (0.6) Any 8.0
(range: <
1-16)
Not given Direct
radioimmunoassay
1.2 (0.6 to 2.4) 0.57 Not done N/A
ORDET
(Micheli et
al. 2004)
65/243 44.3 (4.9) Luteal 5.2
(range: 3
to 8)
Not given Direct
radioimmunoassay
1.0 (ref)
1.1 (0.4 to3.0)
2.2 (0.6 to7.6)
0.28 1.0 (ref)
1.9 (0.6 to 5.8)
3.1 (0.9 to10.9)
0.08
EPIC
(Kaaks et
al. 2005)
370/726 45.6 (7.6) Any 2.8
(range: 0.2
to 5.8)
Not given
Age < 49:
47%
Direct
radioimmunoassay
1.0 (ref)
1.4 (1.0 tp 2.1)
1.4 (0.9 to 2.0)
1.7 (1.2 to 2.6)
0.01 Not done N/A
NHS II
(Eliassen
et al.
2006)
197/394 43.4 (3.8) Follicular 2.9
(range: 0.1
to 7.3)
Pred Extraction,
chromatography,
radioimmunoassay
1.0 (ref)
1.3 (0.8 to 2.2)
1.4 (0.8 to 2.3)
1.3 (0.8 to 2.4)
0.35 1.0 (ref)
1.5 (0.8 to 2.6)
1.5 (0.9 to 2.6)
1.6 (0.9 to 2.8)
0.17
Luteal 1.0 (ref)
1.3 (0.8 to 2.3)
1.4 (0.8 to 2.3)
1.6 (0.9 to 2.8)
0.10 1.0 (ref)
0.9 (0.5 to 1.5)
1.3 (0.7 to 2.2)
1.4 (0.8 to 2.5)
0.14
Columbia
Serum
Bank
(Dorgan
et al.
2010)
98/168 44.7 (4.8) Any 14.0
(SD: 6.6)
Not given
Age ≥65:
68%
Extraction,
chromatography,
radioimmunoassay
1.0 (ref)
2.1 (0.9 to 4.8)
1.5 (0.6 to 3.4)
3.3 (1.5 to 7.5)
<
0.01
1.0 (ref)
1.7 (0.7 to 4.2)
1.7 (0.7 to 4.0)
4.2 (1.6 to 10.9)
<
0.01
NYUWHS 356/683 44.3 (4.9) Any 13.1
(SD: 1.9)
Pre: 49%
Post: 51%
Direct
radioimmunoassay
1.0 (ref)
1.5 (0.9 to 2.3)
1.2 (0.7 to 1.9)
1.4 (0.9 to 2.3)
1.8 (1.1 to 2.9)
0.04 1.0 (ref)
1.2 (0.7 to 1.8)
1.5 (0.9 to 2.3)
1.5 (0.9 to 2.3)
1.8 (1.1 to 2.8)
0.01
aWysowski et al. [9] not included in table because no odds ratio was provided (no statistical difference was observed in testosterone concentrations in 17
women). bOdds Ratios (95% CIs) based on a 1 unit increase in the natural log of hormone concentration, tertiles, quartiles, or quintiles of serum concentration.
cBioavailable testosterone (free plus albumin bound) calculated in Dorgan et al. 2010 study. dExcept for five women.
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measurement is quite representative of a woman’s con-
centration over several years. This is despite the fact
that we did not control for time of day of blood dona-
tion, and, therefore, for possible circadian variations of
androgen production. A weakness of our study is that
we used radioimmunassays without an extraction step,
and the sensitivity and specificity of such assays have
been questioned [46,62]. It should be noted, though,
that results from other studies did not appear to vary
according to whether or not a purification step was
used (table 6). A similar observation was made for sex
hormone concentrations in postmenopausal women [1].
Conclusions
In conclusion, and in agreement with other cohorts, we
observed associations between pre-diagnostic concentra-
tions of total and free testosterone in premenopausal
women and risk of breast cancer. These results suggest
that androgen concentrations should be considered for
inclusion in risk prediction models for women between
the ages of 40 and 50, which could help in decision
making regarding both screening and chemoprevention
of breast cancer.
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